Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions.

The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR1 and VEGFR2, which differ considerably in signaling properties.

Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies.

Pathology

 susceptibility to diabetic retinopathy in type 2 diabetes

References

 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669-76. PMID: #12778165#

 Lambrechts D, Storkebaum E, Carmeliet P. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol Med. 2004 Jun;10(6):275-82. PMID: #15177192#

 Greenberg DA, Jin K. VEGF and ALS: the luckiest growth factor? Trends Mol Med. 2004 Jan;10(1):1-3. PMID: #14720577#

 Rabbany SY, Heissig B, Hattori K, Rafii S. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med. 2003 Mar;9(3):109-17. PMID: #12657432#

 Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002 Oct;2(10):795-803. PMID: #12360282#

 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669-76. PMID: #12778165#